Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in
redosable gene therapies for rare diseases today announced the
appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L.
Marantz, MD, PhD, MBA to its board of directors.
“We are pleased to welcome Drs. Mason and Marantz to our board
of directors,” said Krish S. Krishnan, Chairman and Chief Executive
Officer of Krystal Biotech, Inc. “They bring significant gene
therapy translational and rare disease commercial strategy
expertise that will be invaluable as we continue on our mission to
be a fully integrated rare disease company.”
Dr. Mason is a Founder and Chief Scientific Officer at AVROBIO,
a clinical-stage, gene therapy company. He is a clinician-scientist
with over 25 years of cell and gene therapy experience spanning
research and development, clinical medicine, and bioprocessing. He
is a Full Professor of Cell and Gene Therapy in the Advanced Centre
for Biochemical Engineering, University College London. In 2019, he
was elected as a Fellow of The Academy of Medical Sciences. He is
also a Founder and Non-Executive Director of OriBiotech, a company
focused on next-generation fully-automated cell therapy
bioprocessing. Dr. Mason was instrumental in the founding of the
Alliance for Regenerative Medicine (ARM), the UK-Israel Science
Council, and the London Regenerative Medicine Network. He is on the
SAB of number of companies as well as the UK Cell & Gene
Therapy Catapult and the Canadian Centre for the Commercialization
of Regenerative Medicine (CCRM). Dr. Mason is Senior Editor of the
journals, ‘Cell and Gene Therapy Insights’ and ‘Regenerative
Medicine’.
“I am very excited to join the outstanding team at Krystal
Biotech, who are redefining in vivo gene therapy with their
promising, redosable HSV-1-based approach,” said Dr. Mason. “Their
innovative platform appears ideally suited to deliver the
much-needed step change for the treatment of serious skin diseases
at commercial scale, as well as the potential to address additional
target tissues.”
Dr. Marantz has more than 20 years of experience in the
biopharmaceutical industry across roles spanning development,
medical affairs, business development, and commercial strategy in
multiple specialties and rare diseases. She currently serves as the
Senior Vice President, Head of Medical Affairs at Acceleron Pharma.
Prior to joining Acceleron in 2020, Dr. Marantz was Senior Vice
President, Head of Medical Affairs at Alnylam Pharmaceuticals where
she built the medical affairs organization into a global footprint
across 19 countries and led two successful global product launches
(Onpattro and Givlaari). Prior to Alnylam, Dr. Marantz served as
Vice President, Global Medical Affairs, Head of U.S. Medical
Affairs and interim Head of Latin America Medical Affairs at
Alexion Pharmaceuticals where she was responsible for three
marketed rare disease products (Soliris, Strensig, and Kanuma). She
previously held leadership positions at Biogen, ARIAD, and
Millennium Pharmaceuticals across development, medical affairs, and
business development.
“I’m delighted to join the board at such an exciting time as
Krystal looks to commercialize its first product from its
proprietary and differentiated gene therapy technology,” said Dr.
Marantz. “I look forward to contributing to Krystal’s effort to
bring innovative therapies to patients with high unmet need while
continuing to expand its platform and pipeline.”
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene
therapy company leveraging its novel, redosable gene therapy
platform and in-house manufacturing capabilities to develop
therapies to treat serious rare diseases. For more information
please visit http://www.krystalbio.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Krystal Biotech, Inc., including but not
limited to statements about the development of Krystal’s product
candidates, such as plans for the design, conduct and timelines of
ongoing clinical trials of beremagene geperpavec (“B-VEC”), KB105,
KB104, KB301 and KB407; the clinical utility of B-VEC, KB105,
KB104, KB301 and KB407, and Krystal’s plans for filing of
regulatory approvals and efforts to bring B-VEC, KB105, KB104,
KB301 and KB407 to market; the market opportunity for and the
potential market acceptance of B-VEC, KB105, KB104, KB301 and
KB407; plans to pursue research and development of other product
candidates; the sufficiency of Krystal’s existing cash resources;
the unanticipated impact of COVID-19 on Krystal’s business
operations, pre-clinical activities and clinical trials; and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, availability and timing of data from clinical trials,
whether results of early clinical trials or trials will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of product candidates including B-VEC, KB105,
KB104, KB301 and KB407, the sufficiency of cash resources and need
for additional financing and such other important factors as are
set forth under the caption “Risk Factors” in Krystal’s annual and
quarterly reports on file with the U.S. Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Krystal’s views as of the date of this
release. Krystal anticipates that subsequent events and
developments will cause its views to change. However, while Krystal
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Krystal’s views as of any date subsequent to the date
of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210104005173/en/
Investors: Whitney Ijem wijem@krystalbio.com
Media: Mary Coyle TellMed Strategies
mary.coyle@tmstrat.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Aug 2023 to Aug 2024